After FRANCIS: Next steps in the clinical evaluation of varespladib methyl

Future Cardiology

Volumn 7, Issue 1, 2011, Pages 11-18

  Rosenson, Robert S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

FRANCIS; phospholipase inhibitor; secretory phospholipase A2; varespladib methyl

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ESTERASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SECRETORY PHOSPHOLIPASE A2; UNCLASSIFIED DRUG; VARESPLADIB METHYL;

ACUTE CORONARY SYNDROME; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG USE; ENZYME BLOOD LEVEL; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; UNSTABLE ANGINA PECTORIS;

ACETIC ACIDS; ACUTE CORONARY SYNDROME; ANALYSIS OF VARIANCE; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; INDOLES; LOGISTIC MODELS; MALE; MIDDLE AGED; PHOSPHOLIPASES A2, SECRETORY; PYRROLES;

EID: 78650633272     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.118     Document Type: Article

References (26)

1. Rosenson RS. Novel therapies affecting the vascular wall. In: Braunwalds Clinical Lipidology. Ballantyne CM (Ed.). Saunders Elsevier, PA, USA 553-567 (2008).
2. Fuster V, Lois F, Franco M. Early identification of atherosclerotic disease by noninvasive imaging. Nat. Rev. Cardiol. 7, 327-333 (2010).
3. Rudd JHF, Narula J, Strauss W, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography. J. Am. Coll. Cardiol. 55, 2527-2535 (2010).
4. Koenig W, Rosenson RS. Acute-phase reactants and coronary heart disease. Semin. Vasc. Med. 2, 417-428 (2002).
5. Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352, 20-28 (2005).
6. Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to- Zocor Trial. Circulation 114, 281-288 (2006).
7. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98, 839-844 (1998).
8. He L-P, Tang X-Y, Ling W-H, et al. Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies. Heart 96, 339-346 (2010).
9. Smith SC Jr, Milani RV, Arnett DK, et al. Atherosclerotic Vascular Disease Conference: Writing Group II: risk factors. Circulation 109, 2613-2616 (2004).
10. Danesh J, Pepys MB: C-reactive protein and coronary disease: is there a causal link? Circulation 120, 2036-2039 (2009).
11. Rosenson RS. Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc. Drugs Ther. 23, 93-101 (2009).
12. Rosenson RS. Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoproteinassociated phospholipase A2 enzymes. Curr. Opin. Lipidol. 21(6), 473-480 (2010).
13. Rosenson RS, Gelb MH: Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes. Curr. Cardiol. Rep. 11, 445-451 (2009).
14. Kleinman Y, Krul ES, Burnes M, et al. Lipolysis of LDL with phospholipase A2 alters the expression of selected ApoB-100 epitopes and the interaction of LDL with cells. J. Lipid Res. 29, 729-743 (1988).
15. Flood C, Gustafsson M, Pitas RE, et al. Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low density lipoprtoein-containing human apolipoprotein B100. Arterioscler. Thromb. Vasc. Biol. 24, 564-570 (2004).
16. Hanasaki K, Yamada K, Yamamoto S, et al. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J. Biol. Chem. 277, 29116-29124 (2002).
17. Sartripy P, Camejo G, Svensson L, et al. Phospholipase A2 modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. J. Biol. Chem. 274, 25913-25920 (1999).
18. Hakala JK, Oorni K, Pentikainen MO, et al. Lipolysis of LDL by human secretory phospholipase A2 induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler. Thromb. Vasc. Biol. 21, 1053-1058 (2001).
19. Rosenson RS, Hislop C, McConnell D, et al. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a Phase II double-blind, randomised, placebo-controlled trial. Lancet 373, 649-658 (2009).
20. Rosenson RS, Elliott M, Stasiv Y, et al. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. Eur. Heart J. (2010) (Epub ahead of print).
21. Kim YJ, Kim KP, Han SK, et al. Group V phospholipase A2 induces leukotriene biosynthesis in human neutrophils through the activation of group via phospholipase A2. J. Biol. Chem. 277, 36479-36488 (2002).
22. Balboa MA, Balsinde J, Winstead MV, et al. Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages. J. Biol. Chem. 271, 32381-32384 (1996).
23. Antonov AS, Kolodgie FD, Munn DH, et al. Regulation of macrophage foam cell formation by ab3 integrin: potential role in human atherosclerosis. Am. J. Pathol. 165, 247-258 (2004).
24. Rosenson RS, Hislop C, Elliott M, et al. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J. Am. Coll. Cardiol. 56, 1079-1088 (2010).
25. Rosenson RS, Fraser H, Hislop C, et al. Varespladib methyl in cardiovascular disease. Exp. Opin. Invest. Drugs 19, 1245-1255 (2010).
26. VISTA-16 trial: evaluation of safety and efficacy of short-term A-002 treatment in subjects with acute coronary syndromes (NCT01130246). http://clinicaltrials.gov/ct2/show/results/NCT01130246 (Accessed 2 August 2010)